BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Federal Trade Commission
Chinese Patent Office
Covington
Medtronic
Fish and Richardson
Mallinckrodt
Deloitte
Harvard Business School

Generated: January 23, 2018

DrugPatentWatch Database Preview

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER Drug Profile

« Back to Dashboard

When do Cardene In 0.83% Sodium Chloride In Plastic Container patents expire, and what generic alternatives are available?

Cardene In 0.83% Sodium Chloride In Plastic Container is a drug marketed by Chiesi Usa Inc and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-three patent family members in eleven countries.

The generic ingredient in CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER is nicardipine hydrochloride. There are eleven drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the nicardipine hydrochloride profile page.
Summary for CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER
Drug patent expirations by year for CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER
Medical Subject Heading (MeSH) Categories for CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

US Patents and Regulatory Information for CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chiesi Usa Inc CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-004 Nov 7, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Chiesi Usa Inc CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-004 Nov 7, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Chiesi Usa Inc CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-004 Nov 7, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Chiesi Usa Inc CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-004 Nov 7, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,659,290 Methods of preparing pre-mixed, ready-to-use pharmaceutical compositions ➤ Subscribe
9,370,586 Methods of preparing pre-mixed, ready-to-use pharmaceutical compositions ➤ Subscribe
9,549,994 Compositions of nicardipine and sulfoalkylated .beta.-cyclodextrin ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
US Department of Justice
McKesson
Cerilliant
Chubb
Mallinckrodt
Dow
Federal Trade Commission
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot